News

• Serodus ApS will receive final pharmacological reports from last studies with SER130.
• Shareholder meeting will be held in Q1 2026.

Read more here

• Serodus ApS has initiated sale of SER150.
• Serodus ApS will finalize the pharmacological studies of SER130.

Read more here

• Draft report SER150 CL-009 was received and will be discussed with the Australian contract organisation and the Serodus biostatistician consultant.
• In March 2025 the company launched a Private Placement with a following Subsequent Offering. The commitment amounted to NOK 20,1 million.

Read more here

Download investor letter here

Download the minutes here

Serodus AS – Publishes 2024 Annual Report

Download it here

Download notice here

• Unblinding of the database after SER150 CL-009 was delayed.
• Calculation of SER150 effect on kidney function compared to placebo is consequently also delayed.

Read more here

• Contacts to banks for assisting Serodus in selling Serodus AS, the pipeline or the individual assets was initiated.
• Database for SER150 CL-009 is expected to be unblinded late August or early September.

Read more here

Download the minutes here